Literature DB >> 22337311

A survey for neutralizing antibodies to the three types of poliovirus among children in Maiduguri, Nigeria.

M M Baba1, B A Haruna, O Ogunmola, J P Ambe, N N Shidali, B Oderinde, A Marcello, M Talle.   

Abstract

The milestone in polio eradication program is to protect effectively children aged 0-5 years against the three serotypes of poliovirus. It became necessary to measure the level of neutralizing antibodies to the three poliovirus types in an endemic State in Nigeria. Neutralizing antibodies to the poliovirus types among children aged 0-5 years was estimated using micro neutralization assay. Of 129 children, 99 (76.8%), 95 (73.6%), and 95 (73.6%) had neutralizing antibodies with the geometric mean titer of 42.7, 31.3, and 33.2 for the poliovirus type 1, 2, and 3, respectively. Fifty-three percent of the children were protected against the three types of poliovirus. Combination of poliovirus types 1 and 2, 1 and 3, and 2 and 3 were neutralized by 62.8, 58.9, and 61.2% of the children studied, respectively. Only poliovirus type 1 induced antibody titres ≥1:1,024. The number of children with neutralizing antibodies after receiving three doses was significantly higher than those who received one or two doses of oral polio vaccine (P ≤ 0.05). However, those who received more than three doses of oral polio vaccine showed no significant difference in their antibody response. The existence of immunity gap poses a risk of re-emergence of the paralytic poliovirus. The existence of unimmunized and unprotected children along with high birth rate could impede the success of polio vaccination in Nigeria. Elimination of non-compliance to polio vaccine, promotion of health education and documented evidence of vaccination of each child with the parents may facilitate the success of polio eradication program in Nigeria.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22337311     DOI: 10.1002/jmv.23228

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Immunity to poliovirus serotypes in children population of selected communities in South-west, Nigeria.

Authors:  Johnson Adekunle Adeniji; Folakemi Abiodun Osundare; Olubusuyi Moses Adewumi; Anyebe Bernard Onoja; Ademola Hezekiah Fagbami
Journal:  Afr J Infect Dis       Date:  2015

2.  Assessment of poliovirus antibody seroprevalence in polio high risk areas of West Africa.

Authors:  Oumar Guindo; Ondrej Mach; Seydou Doumbia; Daniel K Ekra; Abdoul H Beavogui; William C Weldon; M Steven Oberste; Roland W Sutter
Journal:  Vaccine       Date:  2018-01-19       Impact factor: 4.169

3.  Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar.

Authors:  Richter Razafindratsimandresy; Ondrej Mach; Jean-Michel Heraud; Barivola Bernardson; William C Weldon; M Steven Oberste; Roland W Sutter
Journal:  Heliyon       Date:  2018-03-07

4.  Poliovirus antibody levels and lameness among individuals in three regions of Ghana.

Authors:  Joseph Kwadwo Larbi Opare; John Kofi Odoom; Patricia Akweongo; Edwin Andrew Afari; Matilda Pappoe
Journal:  Hum Vaccin Immunother       Date:  2019-07-25       Impact factor: 3.452

5.  Poliovirus neutralizing antibody levels among individuals in three regions of Ghana.

Authors:  Joseph Kl Opare; Patricia Akweongo; Edwin A Afari; John K Odoom
Journal:  Ghana Med J       Date:  2019-06

6.  Achieving High Poliovirus Antibody Seroprevalence in Areas at Risk of Vaccine-Derived Poliovirus Transmission-Niger Experience.

Authors:  Sani Ousmane; Dan Dano Ibrahim; Ajay Goel; William S Hendley; Bernardo A Mainou; Tess Palmer; Aissata Diaha; Sharon A Greene; Ondrej Mach
Journal:  Open Forum Infect Dis       Date:  2021-05-06       Impact factor: 3.835

7.  Factors determining anti-poliovirus type 3 antibodies among orally immunised Indian infants.

Authors:  Saravanakumar Puthupalayam Kaliappan; Srinivasan Venugopal; Sidhartha Giri; Ira Praharaj; Arun S Karthikeyan; Sudhir Babji; Jacob John; Jayaprakash Muliyil; Nicholas Grassly; Gagandeep Kang
Journal:  Vaccine       Date:  2016-08-24       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.